Now that Ocular Therapeutix Inc. has whiffed with a steel blade quick-fix to a particulates issue that delayed approval of its Dextenza (dexamethasone intracanalicular insert), the firm has a new CEO and a more measured plan for getting back into FDA's good graces.
Ocular's final closeout response to pre-approval inspection Form 483 findings, announced July 10, arrived at FDA too late to dissuade the agency from
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?